Dynavox Inc: (OTC: DVOX)
$0.09
0.01 (5.88%)
Volume 163,627
May 22 03:56 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 0.08 - 0.10 |
| 52wk Low - High | 0.07 - 1.60 |
| Previous Close | 0.09 |
| Avg. Volume | 139,915 |
| Industry | MED PRODUCTS |
| Market Cap | 1.02 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.95 |
| PE (Forward) | 2.25 |
| Current Year Est. | 0.04 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
184 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 2.25 |
| PEG Ratio | 0.15 |
| Current Year Est. | 0.04 |
| Current Quarter Estimate | 0.00 |
| Most Accurate Estimate | NA |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 09-19-2013 |
| EPS Last Year | -0.02 |
| Expected Earnings Growth | 15.00% |
Company Description
DynaVox Inc. is engaged in developing and marketing software, devices and content to assist people in overcoming their speech, language or learning disabilities. The Company's speech generating devices are used by those who are unable to speak, such as adults with amyotrophic lateral sclerosis, or ALS, often referred to as Lou Gehrig's disease, strokes or traumatic brain injuries and children with cerebral palsy, autism or other disorders. Its portfolio of speech generating devices provides users with a broad range of features and designs and makes use of an array of adaptive technology that permits users with physical or cognitive limitations to access and control the devices. DynaVox's mission is to enable its customers to realize their full communication and education potential by developing industry-leading devices, software and content and by providing the services to support them.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (06/2013) |
Next Year (06/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.00 | 0.01 | 0.04 | 0.05 |
| Number of Estimates | 1 | 1 | 1 | 1 |
| Low Estimate | 0.00 | 0.01 | 0.04 | 0.05 |
| High Estimate | 0.00 | 0.01 | 0.04 | NA |
| Year Ago EPS | 0.00 | 0.01 | 0.14 | 0.04 |
| EPS Growth | NA | 0.00% | -71.43% | 25.00% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| DYNAVOX INC-A | DVOX | 0.09 | |
|
| ATRICURE INC | ATRC | 9.14 | |
|
| CONCEPTUS INC | CPTS | 30.94 | |
|
| INVIVO THERAPT | NVIV | 2.90 | |
|
| TRANS1 INC | TSON | 1.80 | |
|
| ABAXIS INC | ABAX | 43.51 | |
|
| ADVAXIS INC | ADXS | 0.04 | |
|
| BAXTER INTL | BAX | 72.30 | |
|
| BIO-RAD LABS -A | BIO | 115.39 | |
|
| BIOLIFE SOL INC | BLFS | 0.37 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Another Deal for Unilife Corp.
Apr 10, 2013
LIFE Plans to Implement cGMP
Apr 02, 2013
Covidien Studies Reach Milestone
Feb 25, 2013
Zacks #5 Rank Additions for Thursday
Oct 11, 2012
Report for DVOX
Apr 16, 2013
Financials
| EPS TTM | -0.02 |
| Sales | 97 |
| Net Income | -12 |
| Price/Earnings | NA |
| Price/Book | 0.07 |
| Price/Cash Flow | 0.11 |
| Price/Sales | 0.01 |
News
DynaVox Reports Third Quarter Fiscal Year 2013 Results - Globenewswire
May 17, 2013
DynaVox Announces Receipt of NASDAQ Notice to Delist Shares - Globenewswire
Apr 10, 2013
DynaVox Q2 net income down - Datamonitor
Feb 20, 2013
DynaVox Reports Second Quarter Fiscal Year 2013 Results - Globenewswire
Feb 11, 2013
DynaVox Inc. (DVOX) Corporate Event Announcement Notice - Comtex
Nov 14, 2012
DynaVox to Present at the 24th Annual Piper Jaffray Healthcare Conference - Comtex
Nov 14, 2012
Earnings Scheduled For November 13, 2012 - Benzinga
Nov 13, 2012
DynaVox Inc. (DVOX) Corporate Event Announcement Notice - Comtex
Oct 30, 2012
Broker Recommendations
| Current ABR | 2.00 |
| ABR (Last Week) | 2.00 |
| # of recs in ABR | 2 |
| Average Target Price | 1.00 |
| Industry Rank by ABR | 184 out of 265 |
| Rank in Industry | 5 out of 73 |
